Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to evaluate antivirial drug favipiravir in clinical trials to treat patients with Covid-19. Favipiravir is a generic version of Fujifilm Toyama Chemical’s influenza drug Avigan, which holds approval in Japan for treating new influenza virus infections. Glenmark developed the drug’s API and formulations internally. Following the regulatory approval, the new trial will assess the product in Covid-19 patients with mild to moderate infection. Around 150 patients will be enrolled for the study. Participants will be given favipiravir plus standard supportive care or only standard supportive care. Treatment duration of the trial is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation. Glenmark Pharmaceuticals Global R&D executive...